The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Study Type
OBSERVATIONAL
Enrollment
800
ProNephro AKI™ (NGAL) is an immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine.
The University of Alabama
Birmingham, Alabama, United States
UC Davis
Sacramento, California, United States
Yale University
New Haven, Connecticut, United States
Cut off Establishment
The primary objective is to establish the cut-off value for the ProNephro AKI (NGAL) in critically ill adult patients (age 22 and older) admitted to ICU when used as an aid in risk assessment of the development of moderate to severe acute kidney injury (KDIGO stage 2/3) within 48-72 hrs. after admission.
Time frame: 24hrs after ICU admission
Sub-Group analysis
Secondary objective is to explore independent cut-offs and estimate performance for NGAL in urine for the following patient subgroups: Patients after cardiac surgery Patients with decompensating cirrhosis Patients with sepsis Male vs female subjects Sensitivity, specificity, negative and positive predictive values are to be calculated as applicable.
Time frame: 24hrs after ICU admission
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Chicago
Chicago, Illinois, United States
Johns Hopkins University
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
University of New Mexico
Albuquerque, New Mexico, United States
Columbia University
New York, New York, United States
Wake Forest University
Winston-Salem, North Carolina, United States
...and 2 more locations